Skip to main content

Table 2 Initial treatment response to different initial afatinib doses

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Variables All patients Afatinib 30 mg daily Afatinib 40 mg daily P value
Initial response to afatinib treatment -n (%)     0.1661
 Complete response 2 (1%) 1 (1%) 1 (1%)  
 Partial response 138 (77%) 75 (74%) 63 (82%)  
 Stable disease 35 (20%) 25 (25%) 10 (13%)  
 Progressive disease 4 (2%) 1 (1%) 3 (4%)  
Disease control rate with afatinib treatment (%) 175 (98%) 101 (99%) 74 (96%) 0.1913
Response rate with afatinib treatment (%) 140 (78%) 76 (75%) 64 (83%) 0.1672